Imatinib mesylate, 98%, a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50 =100 nM) tyrosine kinases

Name: Imatinib mesylate, 98%, a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50 =100 nM) tyrosine kinases | 220127-57-1
Brand: J&K Chemical
SKU: JK194937_50_MG
Price: 22.0 USD
Availability: OutOfStock

Cat. No JK194937_50_MG

Vendor: J&K Chemical

Product Information

Product Name

Imatinib mesylate, 98%, a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50 =100 nM) tyrosine kinases

Brand Name

J&K

Product Number

194937

CAS

220127-57-1

Molecular Formula

C30H35N7O4S

Molecular Weight

589.72

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

123596

IUPAC Name

methanesulfonic acid;4-(4-methylpiperazin-1-yl)methyl-N-4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenylbenzamide

InChI Key

YLMAHDNUQAMNNX-UHFFFAOYSA-N

SMILES

CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O

Properties

Melting Point

214-224

Safety Information

GHS Symbols

Signal Word

Warning

Hazard Statement

H302

Precautionary Statement

P264

P270

P330

P501

P301+P317

Storage Condition

Freezer -20℃

References Data Source From Pubchem

How I treat chronic myeloid leukemia in children and adolescents

Publication Name: Blood

Publication Date: 2026-01-22

DOI: 10.1182/blood.2024026514

Path sampling challenges in large biomolecular systems: RETIS and REPPTIS for ABL-imatinib kinetics

Publication Name: Biophysical Journal

Publication Date: 2025-11-18

DOI: 10.1016/j.bpj.2025.04.020

Reciprocal c-Abl-GPx1 regulation controls CA1 neuronal viability to oxidative stress via ERK1/2-DRP1-mediated mitochondrial dynamics

Publication Name: Neuropharmacology

Publication Date: 2025-11-01

DOI: 10.1016/j.neuropharm.2025.110586

Poly Lactic Co-glycolic Acid d-α-tocopheryl Polyethylene Glycol 1000 Succinate Fabricated Polyethylene Glycol Hybrid Nanoparticles of Imatinib Mesylate for the Treatment of Glioblastoma Multiforme

Publication Name: Current Medicinal Chemistry

Publication Date: 2025-11

DOI: 10.2174/0109298673323270241118103546

Unraveling the complexity of glioblastoma microenvironment: A comparative study of 3D and 2D cultures in response to combination drug therapy

Publication Name: Brain Research

Publication Date: 2025-10-01

DOI: 10.1016/j.brainres.2025.149783

Imatinib mesylate, 98%, a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50 =100 nM) tyrosine kinases

Product Information

General Information

Properties

Safety Information

References Data Source From Pubchem

How I treat chronic myeloid leukemia in children and adolescents

Path sampling challenges in large biomolecular systems: RETIS and REPPTIS for ABL-imatinib kinetics

Reciprocal c-Abl-GPx1 regulation controls CA1 neuronal viability to oxidative stress via ERK1/2-DRP1-mediated mitochondrial dynamics

Poly Lactic Co-glycolic Acid d-α-tocopheryl Polyethylene Glycol 1000 Succinate Fabricated Polyethylene Glycol Hybrid Nanoparticles of Imatinib Mesylate for the Treatment of Glioblastoma Multiforme

Unraveling the complexity of glioblastoma microenvironment: A comparative study of 3D and 2D cultures in response to combination drug therapy